BDP5290 is primarily utilized in the development of therapeutic agents targeting specific diseases, particularly in oncology. It functions as a potent inhibitor of certain enzymes or proteins that are crucial for the survival and proliferation of cancer cells. By blocking these targets, it helps to halt tumor growth and induce apoptosis in malignant cells. This makes it a promising candidate for use in chemotherapy regimens, especially for cancers that are resistant to conventional treatments. Additionally, it is being studied for its potential in combination therapies to enhance efficacy and reduce drug resistance. Its application extends to preclinical and clinical research, where it is evaluated for safety, pharmacokinetics, and therapeutic effectiveness.